Ulixacaltamide

Praxis Precision Medicines Advances Key Regulatory Programs

BOSTON, August 6, 2026 Praxis Precision Medicines reported its second quarter 2026 financial results, highlighting continued regulatory progress for...

By cGxPwire Editor
August 8, 2026

Bio-Pharma

Praxis and Remagine Collaborate on Ulixacaltamide

BOSTON, Mass. and AUSTIN, Texas, July 7, 2026 Praxis Precision Medicines and Remagine Labs have entered into a strategic...

By cGxPwire Editor
July 8, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

Ulixacaltamide

Praxis Precision Medicines Advances Key Regulatory Programs

Praxis and Remagine Collaborate on Ulixacaltamide